medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-12-106-110medsovet-1442Research ArticleПРЕ- И ПОСТМЕНОПАУЗАPRE- AND POSTMENOPAUSEИНДИВИДУАЛЬНЫЙ ПОДХОД К МИКРОДОЗИРОВАННОМУ РЕЖИМУ МЕНОПАУЗАЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ У ПАЦИЕНТОК СТАРШЕ 60 ЛЕТINDIVIDUAL APPROACH TO ULTRA LOSE DOSE REGIME OF MENOPAUSAL HORMONAL THERAPY IN PATIENTS AGED OVER 60КарахалисЛ. Ю.KarakhalisL. Y.ПенжоянГ. А.PenzhoyanG. A.МогилинаМ. Н.MogilinaM. N.АрутюноваЕ. В.ArutyunovaE. V.Кубанский государственный медицинский университет, КраснодарРоссияKuban State Medical University, KrasnodarRussian Federation201630122016012106110Copyright © Карахалис Л.Ю., Пенжоян Г.А., Могилина М.Н., Арутюнова Е.В., 20162016Карахалис Л.Ю., Пенжоян Г.А., Могилина М.Н., Арутюнова Е.В.Karakhalis L.Y., Penzhoyan G.A., Mogilina M.N., Arutyunova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1442

Менопаузальная гормональная терапия сегодня представлена  ультранизкими дозами в лице препарата Анжелик® Микро, что позволяет продолжить МГТ у пациенток в возрасте старше 60–65 лет и выбрать индивидуальный вид МГТ.

менопаузальная гормональная терапияультранизкие дозыmenopausal hormonal therapyultra low dosesReferencesSchneider HPG. The view of the International Menopause Society on The WHI / Взгляд Международного Общества по Менопаузе на исследование «Инициатива во имя здоровья женщин»/ Climacteric, 2002, 5(3): 211-216.Schneider HPG. The view of the International Menopause Society on The WHI / Взгляд Международного Общества по Менопаузе на исследование «Инициатива во имя здоровья женщин»/ Climacteric, 2002, 5(3): 211-216.Терапия эстрогенами и прогестагенами у женщин в преи постменопаузе. Заявление Североамериканского общества по менопаузе (NAMS). Menopause, 2003, 10: 6-12./ Therapy by estrogens and progestagens in women in preand post-menopause. Statement of the North American Menopause Society (NAMS). Menopause. 2003, 10: 6-12.Терапия эстрогенами и прогестагенами у женщин в преи постменопаузе. Заявление Североамериканского общества по менопаузе (NAMS). Menopause, 2003, 10: 6-12./ Therapy by estrogens and progestagens in women in preand post-menopause. Statement of the North American Menopause Society (NAMS). Menopause. 2003, 10: 6-12.Reitz C et al. Epidemiology of Alzheimer disease. Nat Rev Neurol, 2011. 7: 137-52.Reitz C et al. Epidemiology of Alzheimer disease. Nat Rev Neurol, 2011. 7: 137-52.Henderson VW. Three Midlife Strategies to Prevent Cognitive Impairment Due to Alzheimer’s Disease. Climacteric, 2014, 17(Suppl 2): 38-46.Henderson VW. Three Midlife Strategies to Prevent Cognitive Impairment Due to Alzheimer’s Disease. Climacteric, 2014, 17(Suppl 2): 38-46.Erickson KI et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA, 2011, 108: 3017-22.Erickson KI et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA, 2011, 108: 3017-22.Kobilo T et al. Running is the neurogenic and neurotrophic stimulus in environmental enrichment. Learn Mem, 2011, 18: 605-9.Kobilo T et al. Running is the neurogenic and neurotrophic stimulus in environmental enrichment. Learn Mem, 2011, 18: 605-9.De Villiers TJ et al. Global Consensus Statement on menopausal hormone therapy. Climacteric, 2013, 16: 203-204.De Villiers TJ et al. Global Consensus Statement on menopausal hormone therapy. Climacteric, 2013, 16: 203-204.Practical recommendations for hormone replacement therapy in periand postmenopause. Recommendations from an Expert Workshop 16-17 Feb 2004. Climacteric, 2004, 7: 210-216.Practical recommendations for hormone replacement therapy in periand postmenopause. Recommendations from an Expert Workshop 16-17 Feb 2004. Climacteric, 2004, 7: 210-216.Schierbeck LL, Reinmark L, Toftena CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ, 2012. DOI: 10.1136/bmj.e6409.Schierbeck LL, Reinmark L, Toftena CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ, 2012. DOI: 10.1136/bmj.e6409.The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause, 2012, 19(3): 257-270.The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause, 2012, 19(3): 257-270.Kronos Longevity Research Institute. Hormone therapy has many favorable effects in newly menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study (KEEPS) [press release]. October 3, 2012. N. Panay. Climacteric, 2012, 15: 511-512.Kronos Longevity Research Institute. Hormone therapy has many favorable effects in newly menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study (KEEPS) [press release]. October 3, 2012. N. Panay. Climacteric, 2012, 15: 511-512.de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric, 2013, 16: 203-204.de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric, 2013, 16: 203-204.Lobo R, Davis SR, De Villiers T. Climacteric, 2014, 17: 1-17.Lobo R, Davis SR, De Villiers T. Climacteric, 2014, 17: 1-17.Baber RJ et al. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016, 19: 109-150.Baber RJ et al. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016, 19: 109-150.Fredi Kronenberg «Hot Flashes: Epidemiology and Physiology», department of Rehabilitation Medicine, Colambia University, College of phisicians&Surgeons, New York 10032, II part, 52-86.Fredi Kronenberg «Hot Flashes: Epidemiology and Physiology», department of Rehabilitation Medicine, Colambia University, College of phisicians&Surgeons, New York 10032, II part, 52-86.http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Gynecologic_Practice/Hormone_Therapy_and_Heart_Disease.http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Gynecologic_Practice/Hormone_Therapy_and_Heart_Disease.Freeman EW et al. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause, 2014 Jan 27, 21(9): 924-32.Freeman EW et al. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause, 2014 Jan 27, 21(9): 924-32.Archer D et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause, 2005, 12: 716-727.Archer D et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause, 2005, 12: 716-727.Ruebiq A. Drospirenone: a new cardiovascularactive progestin with antialdosterone and antiandrogenic properties. Climacteric, 2003 Oct 6, Suppl. 3: 49-54.Ruebiq A. Drospirenone: a new cardiovascularactive progestin with antialdosterone and antiandrogenic properties. Climacteric, 2003 Oct 6, Suppl. 3: 49-54.Gude K. EURAS-HRT (European Active Surveillance Study of Women taking HRT). FIGO, Rome, 2012.Gude K. EURAS-HRT (European Active Surveillance Study of Women taking HRT). FIGO, Rome, 2012.Warming L et al. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004, 7: 103-111.Warming L et al. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004, 7: 103-111.Modified from Archer D., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause, 2005, 12: 716-727.Modified from Archer D., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause, 2005, 12: 716-727.Norman RJ. Oestrogen and progestogen hormone replacement therapy for perimenopausal and postmenopausal women: weight and body distribution (Cochrane review). In The Cochrane Library, 3, 2001. Oxford: Update software; Menopause. Vol 17, 2, 2010 Estrogen and progestogen use in postmenopausal women: 2010 Position statement of the North American Menopause Society 2010.Norman RJ. Oestrogen and progestogen hormone replacement therapy for perimenopausal and postmenopausal women: weight and body distribution (Cochrane review). In The Cochrane Library, 3, 2001. Oxford: Update software; Menopause. Vol 17, 2, 2010 Estrogen and progestogen use in postmenopausal women: 2010 Position statement of the North American Menopause Society 2010.Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al. STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause, 2012, 19(4): 387-95.Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al. STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause, 2012, 19(4): 387-95.Archer DF et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17beta-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2013, 21(3): 227-35.Archer DF et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17beta-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2013, 21(3): 227-35.Updated 2013 IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2013, 16: 316-337.Updated 2013 IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2013, 16: 316-337.Archer DF, Schmelter Th, Schaefers M et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17 β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2014, 21( 3): 227-235.Archer DF, Schmelter Th, Schaefers M et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17 β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2014, 21( 3): 227-235.Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric, 2013, 16: 490-498.Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric, 2013, 16: 490-498.Инструкция по применению лекарственного препарата для медицинского применения Анжелик® Микро. Регистрационный номер ЛП-002845, актуальная версия инструкции от 19.10.2015./Patient Information Leaflet for drug Angeliq®Micro. Registration Number LP-002845, current version of the leaflet dated 19.10.2015.Инструкция по применению лекарственного препарата для медицинского применения Анжелик® Микро. Регистрационный номер ЛП-002845, актуальная версия инструкции от 19.10.2015./Patient Information Leaflet for drug Angeliq®Micro. Registration Number LP-002845, current version of the leaflet dated 19.10.2015.

The authors declare that there are no conflicts of interest present.